- Home
- WSC vs ALKS Comparison
WSC vs ALKS Comparison
Compare WSC & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSC
- ALKS
- Stock Information
- Founded
- WSC 1944
- ALKS 1987
- Country
- WSC United States
- ALKS Ireland
- Employees
- WSC N/A
- ALKS N/A
- Industry
- WSC Misc Corporate Leasing Services
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- WSC Industrials
- ALKS Health Care
- Exchange
- WSC Nasdaq
- ALKS Nasdaq
- Market Cap
- WSC 5.3B
- ALKS 5.1B
- IPO Year
- WSC N/A
- ALKS 1991
- Fundamental
- Price
- WSC $23.71
- ALKS $29.94
- Analyst Decision
- WSC Buy
- ALKS Strong Buy
- Analyst Count
- WSC 7
- ALKS 14
- Target Price
- WSC $36.00
- ALKS $40.64
- AVG Volume (30 Days)
- WSC 2.1M
- ALKS 1.4M
- Earning Date
- WSC 10-29-2025
- ALKS 10-23-2025
- Dividend Yield
- WSC 1.19%
- ALKS N/A
- EPS Growth
- WSC N/A
- ALKS 21.99
- EPS
- WSC 0.59
- ALKS 2.08
- Revenue
- WSC $2,352,581,000.00
- ALKS $1,505,296,000.00
- Revenue This Year
- WSC N/A
- ALKS N/A
- Revenue Next Year
- WSC $3.15
- ALKS $1.66
- P/E Ratio
- WSC $40.27
- ALKS $14.40
- Revenue Growth
- WSC N/A
- ALKS N/A
- 52 Week Low
- WSC $21.91
- ALKS $25.56
- 52 Week High
- WSC $42.15
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- WSC 38.71
- ALKS 59.07
- Support Level
- WSC $22.86
- ALKS $28.77
- Resistance Level
- WSC $25.08
- ALKS $31.69
- Average True Range (ATR)
- WSC 0.73
- ALKS 0.85
- MACD
- WSC 0.07
- ALKS 0.11
- Stochastic Oscillator
- WSC 36.64
- ALKS 51.25
About WSC WillScot Mobile Mini Holdings Corp.
WillScot Holdings Corp designs, delivers, and services onsite, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company includes modular office complexes, mobile offices, portable storage containers, and others.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.